These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 26983850

  • 1. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
    Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR.
    Blood; 2016 Apr 28; 127(17):2144-54. PubMed ID: 26983850
    [Abstract] [Full Text] [Related]

  • 2. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.
    Weiss JM, Chen W, Nyuydzefe MS, Trzeciak A, Flynn R, Tonra JR, Marusic S, Blazar BR, Waksal SD, Zanin-Zhorov A.
    Sci Signal; 2016 Jul 19; 9(437):ra73. PubMed ID: 27436361
    [Abstract] [Full Text] [Related]

  • 3. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X, Wang Y, Huang X, Geng S, Li C, Zeng L, Huang L, Du X, Weng J, Lai P.
    Int Immunopharmacol; 2023 Apr 19; 117():109746. PubMed ID: 36827923
    [Abstract] [Full Text] [Related]

  • 4. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
    Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD.
    Proc Natl Acad Sci U S A; 2014 Nov 25; 111(47):16814-9. PubMed ID: 25385601
    [Abstract] [Full Text] [Related]

  • 5. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
    Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.
    Am J Transplant; 2019 Jun 25; 19(6):1820-1830. PubMed ID: 30748099
    [Abstract] [Full Text] [Related]

  • 6. ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.
    Nalkurthi C, Schroder WA, Melino M, Irvine KM, Nyuydzefe M, Chen W, Liu J, Teng MWL, Hill GR, Bertolino P, Blazar BR, Miller GC, Clouston AD, Zanin-Zhorov A, MacDonald KPA.
    JHEP Rep; 2022 Jan 25; 4(1):100386. PubMed ID: 34917911
    [Abstract] [Full Text] [Related]

  • 7. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
    Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR.
    Blood; 2019 Jan 03; 133(1):94-99. PubMed ID: 30279226
    [Abstract] [Full Text] [Related]

  • 8. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
    Matsushita T, Date M, Kano M, Mizumaki K, Tennichi M, Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K.
    Am J Pathol; 2017 Apr 03; 187(4):841-850. PubMed ID: 28189565
    [Abstract] [Full Text] [Related]

  • 9. The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6.
    Tengesdal IW, Kitzenberg D, Li S, Nyuydzefe MS, Chen W, Weiss JM, Zhang J, Waksal SD, Zanin-Zhorov A, Dinarello CA.
    Eur J Immunol; 2018 Oct 03; 48(10):1679-1686. PubMed ID: 30098001
    [Abstract] [Full Text] [Related]

  • 10. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
    Radojcic V, Paz K, Chung J, Du J, Perkey ET, Flynn R, Ivcevic S, Zaiken M, Friedman A, Yan M, Pletneva MA, Sarantopoulos S, Siebel CW, Blazar BR, Maillard I.
    Blood; 2018 Nov 15; 132(20):2188-2200. PubMed ID: 30181175
    [Abstract] [Full Text] [Related]

  • 11. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
    Belle L, Fransolet G, Somja J, Binsfeld M, Delvenne P, Drion P, Hannon M, Beguin Y, Ehx G, Baron F.
    PLoS One; 2016 Nov 15; 11(12):e0167997. PubMed ID: 27942010
    [Abstract] [Full Text] [Related]

  • 12. Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.
    Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D.
    Nat Commun; 2017 Oct 17; 8(1):978. PubMed ID: 29042531
    [Abstract] [Full Text] [Related]

  • 13. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
    Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR.
    Blood; 2017 May 04; 129(18):2570-2580. PubMed ID: 28254742
    [Abstract] [Full Text] [Related]

  • 14. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
    Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR.
    Blood; 2015 Jun 25; 125(26):4085-94. PubMed ID: 25852057
    [Abstract] [Full Text] [Related]

  • 15. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ.
    J Clin Oncol; 2021 Jun 10; 39(17):1888-1898. PubMed ID: 33877856
    [Abstract] [Full Text] [Related]

  • 16. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T.
    J Dermatol Sci; 2014 Jun 10; 74(3):214-21. PubMed ID: 24679982
    [Abstract] [Full Text] [Related]

  • 17. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.
    Lee SH, Moon SJ, Park MJ, Kim EK, Moon YM, Cho ML.
    Immunol Lett; 2014 Jul 10; 160(1):79-88. PubMed ID: 24718277
    [Abstract] [Full Text] [Related]

  • 18. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
    Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY.
    Exp Hematol; 2006 Jun 10; 34(6):776-87. PubMed ID: 16728283
    [Abstract] [Full Text] [Related]

  • 19. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
    Palaniyandi S, Strattan E, Kumari R, Mysinger M, Hakim N, Kesler MV, Apatira M, Bittencourt F, Wang L, Jia Z, Gururaja TL, Hill RJ, Hildebrandt GC.
    Bone Marrow Transplant; 2023 Aug 10; 58(8):924-935. PubMed ID: 37160943
    [Abstract] [Full Text] [Related]

  • 20. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease.
    Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A.
    Exp Hematol; 1997 Mar 10; 25(3):238-45. PubMed ID: 9091300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.